Profile data is unavailable for this security.
About the company
Jiangsu Aidea Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sales of human-source protein products. The Company is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The Company is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The Company's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The Company mainly distributes its products within domestic market.
- Revenue in CNY (TTM)408.68m
- Net income in CNY-104.55m
- Incorporated2009
- Employees476.00
- LocationJiangsu Aidea Pharmaceutical Co LtdNo. 69Xinganquan West Road, Hanjiang DistrictYANGZHOU 225008ChinaCHN
- Phone+86 51 482090238
- Fax+86 51 487736366
- Websitehttps://www.aidea.com.cn
More ▼
Mergers & acquisitions
| Acquired company | 688488:SHH since announced | Transaction value |
|---|---|---|
| Nanjing Nanda Pharmaceutical Co Ltd | -38.63% | 20.59m |
Data delayed at least 15 minutes, as of Nov 05 2024 07:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 211.45m | 3.70bn | 1.16k | 17.49 | 1.96 | -- | 2.56 | 2.25 | 2.25 | 15.42 | 20.06 | 0.6426 | 1.49 | 9.74 | 1,244,707.00 | 8.34 | 11.21 | 9.79 | 14.05 | 61.32 | 69.00 | 12.98 | 13.96 | 3.18 | -- | 0.0566 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 846.29m | 114.79m | 3.80bn | 447.00 | 32.48 | 1.19 | -- | 4.49 | 0.7311 | 0.7311 | 5.38 | 20.03 | 0.2178 | 1.95 | 2.90 | 1,893,258.00 | 3.81 | 5.43 | 4.48 | 6.24 | 87.83 | 89.93 | 17.52 | 20.76 | 3.36 | -- | 0.0582 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Jiangsu Aidea Pharmaceutical Co Ltd | 408.68m | -104.55m | 3.88bn | 476.00 | -- | 3.62 | -- | 9.48 | -0.2384 | -0.2384 | 0.9459 | 2.54 | 0.2193 | 0.9553 | 2.66 | 858,576.30 | -5.65 | -2.40 | -8.32 | -2.85 | 48.96 | 39.00 | -25.77 | -10.15 | 1.11 | -- | 0.3018 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
| Shanghai Fudan Forward S&T Co Ltd | 638.98m | -15.28m | 3.91bn | 1.36k | -- | 5.06 | -- | 6.12 | -0.0222 | -0.0222 | 0.9345 | 1.13 | 0.3799 | 0.6476 | 8.53 | 468,807.20 | -0.9863 | -0.8781 | -1.68 | -1.53 | 36.63 | 43.22 | -2.60 | -1.85 | 0.413 | -2.40 | 0.3319 | -- | -13.86 | -7.58 | 196.17 | -32.57 | -13.88 | -- |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 2.19bn | 50.41m | 3.91bn | 1.43k | 81.27 | 1.74 | -- | 1.78 | 0.0944 | 0.0944 | 4.11 | 4.41 | 0.6831 | 4.89 | 5.41 | 1,538,342.00 | 1.61 | -0.6002 | 2.02 | -0.7417 | 46.46 | 56.64 | 2.35 | -0.9128 | 2.46 | 23.86 | 0.0908 | -- | -2.00 | 4.79 | 17.41 | -11.68 | -25.97 | -- |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.37bn | 13.89m | 4.02bn | 1.85k | 182.40 | 1.51 | -- | 1.69 | 0.0502 | 0.0502 | 5.72 | 6.08 | 0.4094 | 1.74 | 6.76 | 1,284,337.00 | 0.2471 | 3.30 | 0.4806 | 5.97 | 21.35 | 32.35 | 0.6036 | 8.21 | 0.4855 | 1.21 | 0.4994 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
Data as of Nov 05 2024. Currency figures normalised to Jiangsu Aidea Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
31.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 20.11m | 9.32% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 16.56m | 7.67% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 7.44m | 3.45% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 6.90m | 3.20% |
| Lion Fund Management Co., Ltd.as of 30 Jun 2024 | 5.47m | 2.54% |
| Caitong Fund Management Co., Ltd.as of 30 Jun 2024 | 4.90m | 2.27% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.19m | 1.02% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 2.01m | 0.93% |
| Hotland Innovation Asset Management Co. Ltd.as of 30 Jun 2024 | 1.49m | 0.69% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 1.38m | 0.64% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
